FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a new hydrate of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol hydrochloride salt in the crystalline form with the characteristics below. The hydrate can be used for producing a drug or for treating or preventing a transplanted organ or tissue rejection, or autoimmune diseases in a therapeutically effective amount. The above hydrate is characterised by an X-ray powder diffractogram having peaks at approximately 2.9, 17.2, 30.6, 28.2, 24.4, 8.6 and 25.9 degrees 2-Theta with a limit of error of ±0.2 degrees for each value of 2θ, having a purity of 90% or more, and containing 5.2 to 5.9% of water.
EFFECT: invention also characterises a pharmaceutical composition with using the above hydrate.
4 cl, 4 dwg, 8 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FINGOLIMOD SALTS | 2009 |
|
RU2543621C2 |
| CRYSTALLINE FORMS AND METHODS FOR OBTAINING LENVATINIB BESYLATE | 2019 |
|
RU2801812C2 |
| NOVEL CRYSTALLINE FORMS OF SODIUM SALT OF (4-{4-[5-(6-TRIFLUOROMETHYL-PYRIDIN-3-YLAMINO)PYRIDIN-2-YL]PHENYL}CYCLOHEXYL) ACETIC ACID | 2011 |
|
RU2612556C2 |
| STABLE FORMULATIONS OF IMANITIB | 2008 |
|
RU2470641C2 |
| CRYSTALLINE SOLVATES OF HYDROCHLORIDE 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE | 2012 |
|
RU2619129C2 |
| CRYSTALLINE FORMS OF THE TLR7/TLR8 INHIBITOR | 2019 |
|
RU2792005C2 |
| DOSAGE FORMS, SALTS AND POLYMORPHS OF TRANSNORSERTRALINE AND USING THEM | 2010 |
|
RU2578956C2 |
| VINORELBINE MONOTARTRATE AND ITS PHARMACEUTICAL APPLICATION | 2016 |
|
RU2730521C2 |
| SALTS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASE | 2013 |
|
RU2711077C2 |
| NEW CRYSTALLINE FORM OF 7-BROMO-1-(HYDRAZINOCARBONYL)METHYL-5-PHENYL-1,2-DIHYDRO-3H-1,4-BENZODIAZEPINE-2-ONE AND PHARMACEUTICAL APPLICATION THEREOF | 2021 |
|
RU2780646C1 |
